VIDEO: Secukinumab rapidly effective against ankylosing spondylitis
BOSTON – Secukinumab showed enduring efficacy in ankylosing spondylitis after 52 weeks of treatment, based on data reported at the annual meeting of the American College of Rheumatology. The...